Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects

NCT00375401 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00375401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00375401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2006
Completion date
January 31, 2009
Enrollment
2,536 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

obesity